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Abstract Public transcriptomic studies have shown that sev-
eral genes display pronounced gender differences in their ex-
pression in the human brain, which may influence the mani-
festations and risk for neuronal disorders. Here, we apply a
transcriptome-wide analysis to discover genes with gender-
specific expression and significant alterations in public post-
mortem brain tissue from Alzheimer’s disease (AD) patients
compared to controls. We identify the sex-linked ubiquitin-
specific peptidase 9 (USP9) as an outstanding candidate gene
with highly significant expression differences between the
genders and male-specific underexpression in AD. Since pre-
vious studies have shown that USP9 can modulate the phos-
phorylation of the AD-associated protein MAPT, we investi-
gate functional associations between USP9 and MAPT in fur-
ther detail. After observing a high positive correlation between
the expression of USP9 and MAPT in the public transcripto-
mics data, we show that USP9 knockdown results in signifi-
cantly decreased MAPT expression in a DU145 cell culture
model and a concentration-dependent decrease for the MAPT
orthologs mapta and maptb in a zebrafish model. From the
analysis of microarray and qRT-PCR experiments for the
knockdown in DU145 cells and prior knowledge from the
literature, we derive a data-congruent model for a USP9-de-
pendent regulatory mechanism modulating MAPT expression
via BACH1 and SMAD4. Overall, the analyses suggestUSP9
may contribute to molecular gender differences observed in
tauopathies and provide a new target for intervention strate-
gies to modulate MAPT expression.
Keywords Transcriptomics .Tau .Tauopathies .Alzheimer’s
disease . Gender differences . Zebrafish
Introduction
Gender differences in the incidence and phenotypic manifes-
tations of brain disorders like Alzheimer’s disease (AD) have
been reported in several independent studies [1–5]. Findings
for AD include significantly more severe pathology in women
than inmen [1], faster brain atrophy in females [2], as well as a
higher AD incidence in females after adjusting for differential
survival, which has mainly been observed in the oldest-age
categories [3–5].
Some studies have suggested lifestyle differences as a con-
tributing factor for these gender disparities, e.g., the
Framingham Heart Study indicated that selective survival of
men with a healthier cardiovascular risk profile and hence
lower propensity to dementia could partly explain a higher
lifetime risk for AD inwomen [6].Moreover, hormonal mech-
anisms have been implicated in AD gender differences, and
neuroprotective functions have been proposed for testosterone
[7, 8], estrogen [9], and progesterone [10]. However, studies
according to which the disease incidence rates in other neuro-
degenerative diseases show an almost opposite distribution
between the genders as compared to AD (e.g., a greater risk
for Parkinson’s disease in men than in women [11]), suggest
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that differences in hormonal neuroprotection without disease
specificity are not the only factor influencing the observed
gender differences in neurodegenerative disorders. Similarly,
more severe AD-associated effects of the ε4 variant of the
APOE gene, the largest known genetic risk factor for sporadic
AD, reported for females [12] cannot account for the entire
range of phenotypic differences in the disease between the
genders, because cognitive impairment progresses faster in
women than in men even when considering only individuals
without APOE ε4 alleles [13].
Overall, previous studies suggest that a multitude of factors
is likely to be involved in AD gender differences, and accord-
ingly, system level analyses of biomolecular differences be-
tween the sexes in AD may help to identify and understand
further relevant factors. Although gender-based disease alter-
ations in individual biomolecules are unlikely to explain the
full spectrum of observed gender-specific disease manifesta-
tions, their identification and analysis may provide new
pointers to biomolecules with important regulatory functions
in the studied disease, supporting the design of new therapeu-
tic interventions.
Since major differences in brain gene expression levels
between males and females have previously been reported
[14], but not investigated in the context of AD, we have con-
ducted a corresponding system-wide transcriptome analysis
on public data. In subsequent experiments for the top candi-
date gene identified, the ubiquitin-specific peptidase 9
(USP9), we investigated which potential AD disease media-
tors the gene is linked to.USP9 is a gonosomal gene with a Y-
chromosomal (USP9Y) and an X-chromosomal form. In
humans, USP9X escapes X-inactivation [15]. The gene en-
codes a deubiquitinase [16], removing the ubiquitin moieties
from specific proteins and thereby preventing their
proteasomal degradation [15, 17]. It deubiquitinates
monoubiquitinated SMAD4 and has been shown to be an
essential component of the TGF-beta/BMP signaling cascade
[16] (the full gene names and brief function descriptions for
USP9, SMAD4, and the other main genes discussed in this
manuscript is provided in Table 1).
In this study, we first describe the analyses of public tran-
scriptomics data that led to the identification of USP9 as a
gene with an outstanding gender-linked expression pattern
and significant alterations in AD. We then discuss evidence
for regulatory links between USP9 and the AD-associated
protein tau (MAPT), derived from previous studies in the lit-
erature, as well as USP9 knockdown experiments we per-
formed in two model systems, a zebrafish model and human
DU145 prostate cancer cells. Analyzing the transcriptome al-
terations in the DU145 cells in response to the knockdown
experiments at the level of cellular pathways and molecular
networks, we find significant alterations in cytoskeleton re-
modeling processes and specifically, in the molecular network
of microtubule-associated proteins (MAPs) and tubulins
linked to MAPT. From a network analysis of this dataset, we
derive a model for the involvement of USP9 in the regulation
ofMAPTexpression and phosphorylation and discuss possible
applications for developing USP9-based intervention strate-
gies targeting tau hyperphosphorylation and aggregation in
AD and other tauopathies.
Results and Discussion
USP9Y Displays Significant Gender-Linked Expression
in the Adult Brain and Diminished Expression
in Alzheimer’s Disease
To investigate gender differences in the human brain tran-
scriptome during adulthood which may contribute to sex dif-
ferences observed in AD, wemined large-scale public datasets
for genes that displayed both a generic gender-linked expres-
sion and significant expression alterations in AD. For this
purpose, first, we computed male to female median gene ex-
pression level ratios using postmortemmicroarray data from a
subset of 404 samples from 16 different brain regions across
all unaffected adult individuals in the Human Brain
Transcriptome Project (HBT) [14] (NCBI GEO dataset series
GSE25219; the covered brain regions include orbital, dorso-
lateral, ventrolateral, and medial regions of the prefrontal cor-
tex, primary motor cortex, primary somatosensory cortex,
posterior inferior parietal cortex, primary auditory cortex, su-
perior and inferior temporal cortex, primary visual cortex,
hippocampus, amygdala, striatum, mediodorsal nucleus of
the thalamus, and cerebellar cortex; see the BMethods^ section
for details on data preprocessing and analysis). As expected,
the highest consistent male/female expression ratios across the
16 brain regions were observed for sex-linked genes, the top
five being (ordered by decreasing ratio): PCDH11Y, RPS4Y1,
DDX3Y, USP9Y, and EIF1AY (see Fig. 1a, showing a boxplot
for USP9Y and USP9X as an example).
Next, we used data from an independent late-onset AD
case/control transcriptomics study [19] (NCBI GEO dataset
series GSE44772), covering brain samples from 690 individ-
uals across three brain regions (prefrontal cortex, visual cor-
tex, and cerebellum), to examine which of the identified genes
with significant gender-linked expression in the adult human
brain also displayed significant and consistent gender-specific
expression alterations in AD across the covered brain regions.
The rationale is that genes with robust expression alterations
across multiple brain regions in a single study can be com-
pared qualitatively with gene expression changes observed in
other studies covering the same or further brain regions, to
accumulate evidence for consistent multiregional alteration
patterns. Among the identified genes with consistent multire-
gional gender-linked expression as well as gender-specific
expression alterations in AD, the deubiquitinase USP9Y was
Mol Neurobiol
Table 1 Overview of the main genes discussed in this article
Gene symbol Full gene name Description (from GeneCards [18])
USP9X/Y Ubiquitin specific peptidase 9, X/Y Deubiquitinase, preventing degradation of specific proteins
through the removal of conjugated ubiquitin
MAPT Microtubule-associated protein tau Promotes microtubule assembly and stability; found mutated
in several neurodegenerative disorders
BACH1 BTB and CNC homology 1, basic leucine zipper
transcription factor 1
Transcriptional regulator that acts as repressor for MAPT
SMAD4 SMAD family member 4 Member of the SMAD family of signal transduction proteins,
represses transcription of BACH1
MARK4 MAP/microtubule affinity-regulating kinase 4 Member of the microtubule affinity-regulating kinase family,
phosphorylates MAPT
GSK3B Glycogen synthase kinase 3 beta Serine-threonine kinase, belonging to the glycogen synthase
kinase subfamily, phosphorylates MAPT
Full gene names and descriptions of some of the known relevant gene functions are provided (using information from the GeneCards repository)
Fig. 1 a Left: USP9Y normalized
gene expression levels in
postmortem brain tissue from
adult males and females not
affected by AD from the HBT
dataset (as expected, the signal for
the Y-chromosomal version of the
gene in female samples does not
significantly exceed the baseline,
i.e., no expression is detected);
right: USP9X normalized
expression levels in postmortem
brain tissue from adult males and
females (expression levels are
comparable across the genders,
i.e., USP9X expression in females
does not compensate the absence
of USP9Y expression in females;
see also the comparison across
different age groups in Fig. 2c). b
Boxplot of USP9Y gene
expression levels in human
postmortem hippocampus
samples for incipient, moderate,
and severe cases of male
Alzheimer’s disease patients as
compared to non-demented male
controls (dataset by Blalock
et al.). The reader should note that
normalized expression level
intensities are only comparable
across different genes within one
study but not across different
studies
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the only gene showing a significantly reduced expression in
male AD patients as compared to unaffected male subjects
(adjusted p value <0.05) that matched with the multiregional
changes observed on data from another AD case/control study
with 161 microarray samples (p = 0.003) [20] (NCBI GEO
dataset series GSE5281, covering the brain regions primary
visual cortex, entorhinal cortex, hippocampus, medial tempo-
ral gyrus, posterior cingulated, and superior frontal gyrus) as
well as a further AD case/control study with 30 hippocampal
microarray samples [21] (NCBI GEO dataset series
GSE28146; given the small sample size for the individual
genders, on this third dataset significance could not be shown
independently, p = 0.17, but a statistical meta-analysis across
all datasets confirmed the significant underexpression across
multiple brain regions, p < 2E−05). The dataset by Blalock
et al. additionally groups AD patients into different stages of
progression (Bincipient,^ Bmoderate,^ and Bsevere^ AD), and
in all three stages, a qualitative reduction in median USP9Y
expression is observed as compared to the control samples
(the sample size is however too small to establish
significance for the individual progression groups; see
boxplot in Fig. 1b). Thus, we decided to focus our subsequent
mechanistic investigation on USP9 gene regulation.
Associations Between USP9 Expression
and the Expression and Phosphorylation of Tau
The AD-relatedmicrotubule-associated protein tau (MAPT) is
involved in the stabilization of microtubules, which function
as intracellular transport path [22]. Aggregations of paired
helical filaments (PHFs) of MAPT into neurofibrillary tangles
(NFTs) are known as one of the main hallmarks of AD and are
commonly considered as neurotoxic but have also been pro-
posed to represent secondary protective effects, since the re-
duction in microtubule assembly in AD is independent of
MAPT abnormalities [23].
Similarly, different roles have been suggested for MAPT
phosphorylation in AD, and potential toxic and protective
effects have both been described [24, 25]. USP9 is linked
mechanistically to MAPT phosphorylation. It has been shown
that the X-chromosomal version of USP9 (USP9X)
deubiquitinates the microtubule affinity-regulating kinase 4
(MARK4) [26], which in turn is known to phosphorylate
MAPT [27]. A significant and strong increase of MARK4
expression and MARK4-MAPT interactions in AD brains,
correlating with the Braak stages of the disease, has been
found in postmortem human brains [28]. In a drosophila
Alzheimer’s model, overexpression of the USP9 ortholog faf
was reported to enhance phospho-MAPT-mediated postsyn-
aptic toxicity of amyloid precursor protein (APP)/Aβ-42 [29].
Moreover, USP9X can increase MAPT phosphorylation via a
second mechanism, by deubiquitinating the protein alpha-
synuclein (SNCA) [30], which functions as a connecting
mediator between the glycogen synthase kinase 3β
(GSK3B) and MAPT and has been shown to stimulate
MAPT phosphorylation via GSK3B in vitro [31]. While our
analyses focus on the relations between USP9 and MAPT at
the level of transcriptional regulation (see following sections),
the prior knowledge on the involvement of USP9 in the reg-
ulation of MAPT phosphorylation provides a first line of ev-
idence in support of a close functional relationship between
these two genes/proteins.
For the Y-chromosomal version of USP9 (USP9Y), inter-
actions with MARK4 and SNCA as observed for USP9X
have not been reported so far, but USP9Y has a high sequence
similarity of 93% to USP9X (quantified using the SIAS soft-
ware tool with default settings, see http://imed.med.ucm.
es/Tools, and the canonical protein sequences for UniProt
IDs Q93008 and O00507) and is therefore expected to have
largely similar structure and function (this is also confirmed
by our cell culture model transcriptome analysis, comparing a
USP9X-specific knockdown with aUSP9X/Y knockdown; see
details below).
Apart from previously reported functional relations be-
tween USP9 and MAPT at the protein level, the gene expres-
sion data analyzed here suggests a further possible association
at the transcriptional level, which was analyzed in more detail
via knockdown experiments in this study (see following sec-
tions). For a shared genetic probe for MAPT contained in the
transcriptomics datasets by Liang et al. [20] and Blalock et al.
[21], high positive correlations withUSP9Ywere found across
the male samples (r = 0.483, p = 2.3E−07 for cases and con-
trols combined, and r = 0.376, p = 5.5E−03 in controls only
for the data by Liang et al.; r = 0.425, p = 0.169 for cases and
controls combined, and r = 0.452, p = 0.368 in controls only
on the small dataset by Blalock et al.). Similarly, among the
unaffected male individuals of the older age group (age ≥ 40)
in the HBT dataset, a high correlation between MAPT and
USP9Y was observed (r = 0.480, p = 1.5E−06). Given that a
higher correlation was observed in controls as compared to
cases on the dataset by Blalock et al., as opposed to a lower
correlation in controls compared to cases on the dataset by
Liang et al., the results do not suggest that there is a general
trend of higher MAPT/USP9Y correlations in either case or
control samples. Generally, for larger sample sizes, improved
p value significance scores were obtained for the MAPT/
USP9Y correlation (i.e., when combining case and control
samples as opposed to studying control samples only and
when considering the HBT and Liang et al. datasets as op-
posed to the smaller Blalock et al. dataset).
Age-Dependent Expression of MAPT and USP9
MAPT and USP9Y expression levels were also compared
across different adult age groups using brain transcriptomics
data from individuals unaffected by AD from the Human
Mol Neurobiol
Brain Transcriptome Project (HBT) project [14] (see the
BMethods^ section). In general, we observed a significant de-
crease in the levels ofMAPT in the brain during healthy adult
aging, matching with the results reported in an independent
study [32]. Apart from this overall trend, we noted that the
age-dependent decline in MAPT levels was gender-specific,
with a faster decline in females as compared to males (see
Fig. 2a). However, these gender differences in MAPT expres-
sion alone cannot explain the various gender differences in
AD pathoetiology. Indeed, diverse types of gender differences
have been observed across different MAPT-related diseases,
e.g., a higher male preponderance for frontotemporal demen-
tia [33] as opposed to an opposite risk profile in AD. While
this indicates that MAPT-mediated gender intrinsic
pathoetiology may be modulated also by other factors, it is
perfectly in line with the role of MAPT in tauopathies.
Given the associations betweenUSP9 andMAPT described
above, we also compared the genes in terms of the gender
differences in their expression across different age groups.
As shown in Fig. 2b, median USP9Y levels in males increase
across the first three age groups (12 to 20, 20 to 40, and 40 to
60 years) with a slight relative decrease afterward. These
changes in USP9Y were not compensated by corresponding
increases in USP9X expression in females (see Fig. 2c).
Comparing Fig. 2a, b, the increased USP9Y expression in
higher age groups in males coincides with a slower age-
dependent decline ofMAPT in males as compared to females,
in line with the observed expression level correlations be-
tween USP9Y and MAPT. Since correlations do not necessar-
ily imply a causal regulatory relationship and do not enable a
distinction between cause and effect, we investigated a possi-
ble functional role of USP9Y as a positive regulator ofMAPT
by conducting USP9 knockdown experiments in a zebrafish
model and in the human DU145 cell culture model (see fol-
lowing sections).
Tau Expression Is Decreased After USP9 Knockdown
in Zebrafish
Among potential model organisms for the study of MAPT
regulation, the zebrafish (Danio rerio) is of particular interest,
since it has two MAPT paralogs, mapta and maptb, which
reflect two major groups of MAPT isoforms in humans.
While maptb is predominantly expressed as an isoform with
three tubulin-binding repeats (3R-tau), mapta gives rise to
isoforms with four to six repeats (4-6R-tau) [34, 35], which
significantly increases its affinity for microtubules. Since 3R-
tau and 4R-tau are the two main types of isoforms in humans,
the two zebrafish paralogs may therefore provide a means to
study how other regulatory genes influence the activity of the
two isoforms.
The zebrafish is a well-established vertebrate model for the
study of gene function and human pathologies [36, 37] and its
genome displays a high degree of homology to the human
genome [38]. In this study, we used zebrafish embryos as a
model organism to investigate the possible regulatory relation
between USP9 and MAPT, by studying alterations in the ex-
pression ofmapta andmaptb in response to the knockdown of
the zebrafish USP9 ortholog (usp9). The knockdown was
achieved using usp9 antisense morpholino oligonucleotides
(MO) blocking exon2-intron2 (e2i2) splicing. Gene expres-
sion changes were assessed via qRT-PCR (see the
BMethods^ section for details on the experiment and analysis).
A microscopic analysis comparing uninjected control,
morpholino control, and usp9MO-injected zebrafish showed
no apparent toxic or developmental effect for the knockdown
(see Fig. 3).
As shown in Fig. 4 at 2 days postfertilization, gene expres-
sion in usp9 morphants displays concentration-dependent de-
creases in both mapta and maptb, with a significant reduction
at a MO concentration of 8 ng/injection (p < 0.05 for mapta
and p < 0.01 for maptb). Overall, the results match with the
high positive correlations between USP9Y and MAPT in the
human postmortem transcriptomics datasets, further corrobo-
rating a possible regulatory relationship at the gene expression
level.
Transcriptome-Wide Analysis of USP9X/Y Knockdown
Effects
Gene-Level Expression Analysis of USP9 Knockdown Effects
in DU145 Cells
To assess the biomolecular effects of knocking downUSP9 on
a transcriptome-wide scale, the human DU145 prostate cancer
cell culture model was chosen, after confirming that USP9X,
USP9Y, andMAPT are robustly expressed in this model. As a
tumor-derived and non-neuronal cell line, DU145 can only
provide an approximate model for the regulatory network
around USP9 in primary neuronal cells but has the advantage
that stable expression of all genes of interest could be con-
firmed (see discussion of cell line choice and limitations in the
BMethods^ section).
ShRNA constructs were designed for the knockdown of
USP9X andUSP9X/Y (i.e., targetingUSP9X andUSP9Y joint-
ly) to infer potentialUSP9Y-specific gene alterations indirectly
by comparing both knockdowns. As discussed in the follow-
ing paragraphs, no significant differences in the alteration pat-
terns between the two knockdowns could be detected,
prompting us to combine the knockdown data for the subse-
quent pathway analyses in the section BPathway and network
analysis of USP9 knockdown effects on gene expression in
DU145 cells^. Multiple shRNA constructs were tested for
knockdown efficiency and validated functionality via gene
expression analysis in whole-cell populations. Only the best
construct for each target was used for further experiments.
Mol Neurobiol
Mol Neurobiol
Limitations regarding potentially undetected off-target effects
when using a single shRNA construct per target, as well as the
design and selection of constructs, are covered in the
BMethods^ section. As readout, microarray expression profil-
ing using the Affymetrix GeneChip Human Gene 2.0 ST plat-
form was performed with triplicate samples for each of the
three considered conditions (USP9X/Y knockdown, USP9X
knockdown, scrambled RNA control). This dataset has been
made publicly available in the Gene Expression Omnibus
(GEO) database under series GSE79376. Additionally, for
target genes of interest discussed below, a qRT-PCR validation
was performed (see the BMethods^ section).
After preprocessing and normalization (see the BMethods^
section), expression alterations were investigated first in the
main genes of interest (USP9X/Y and MAPT), filtering the
genetic probes mapping to these genes to retain only those
with an average expression greater than the average expres-
sion across all probes on the chip. As expected, in theUSP9X/
Y knockdown, a marked underexpression was observed in
comparison to the control samples for all 16 genetic probes
mapping to theUSP9X gene and fulfilling the average expres-
sion criterion (see detailed statistics in Suppl. Table S1). For
USP9Y, 14 out of 15 genetic probes passing the average ex-
pression filter also showed a strong reduction in expression
levels (see Suppl. Table S1; the only probe with a positive log-
fold change displayed a higher than average standard devia-
tion and is therefore likely an artifact of noise). These expres-
sion level decreases in the USP9X/Y knockdown were con-
firmed in the qRT-PCR validation (p = 4.6E−10 for USP9X
and p = 4.77E−07 for USP9Y). For the USP9X-specific
knockdown, an underexpression trend was also confirmed
(see Suppl. Table S1).
Interestingly, gene expression levels for MAPT were con-
sistently decreased for the USP9X/Y knockdown for all of
eight filtered MAPT probes and in the qRT-PCR validation,
as well as for all seven probes passing the abovementioned
average expression filter for the USP9X knockdown (see
Suppl. Table S1). These results are in line with the observed
underexpression of mapta and maptb in the zebrafish usp9
knockdown (see Figs. 4 and 5). Moreover, the MAPT probe
expression levels displayed positive average correlations with
those for the USP9X probes (avg. Pearson correlation across
all pairs of filtered probes: r = 0.479, avg. p = 0.096) and
USP9Y probes (avg. r = 0.472, avg. p = 0.082). Similar cor-
relations were also observed in the AD brain transcriptomics
datasets by Liang et al. [20] (r = 0.483, p = 2.3E−07) and
Blalock et al. [21] (r = 0.425, p = 0.169).
To identify possible molecular mechanisms behind the un-
derexpression of MAPT in the USP9X/Y and USP9X knock-
downs, we conducted an upstream network analysis, investi-
gating transcription factors (TFs) known to be involved in the
regulation of MAPT transcription for gene expression alter-
ations in our dataset, using literature-curated TF-target rela-
tionships from the Biobase Proteome™ database (see
http://www.biobase-international.com/proteome-2), the
ResNet® Mammalian database 11 from Elsevier (see
Fig. 2 Boxplot for the normalized gene expression levels of a MAPT, b
USP9Y, and cUSP9X across different age groups in males and females in
the Human Brain Transcriptome dataset (covering only individuals
unaffected by AD). a After 20 years of age, median MAPT levels show
a general trend of continuous decline with age but decrease faster in
females as compared to males (two-sided Welch test p value
significance relative to the 12–20 years age group in the same gender:
*p < 0.05, **p < 0.01, ***p < 0.001). Comparing the differences between
males and females for each age group, females have significantly higher
MAPT levels in the 12–20 years group (p = 1.27E−08), whereas no
significant difference is found in the 20–40 years group, and female
MAPT levels are significantly lower in the 40–60 years group
(p = 0.024) and the >60 years group (p = 0.0012). b Up to the age
group of 40 to 60 years, USP9Y levels tend to increase with higher age
(p value significance for males relative to 12–20 years age group:
*p < 0.05, **p < 0.01, *** p < 0.001). c USP9X levels show no
significant differences in males and females after 20 years of age, i.e.,
during adulthood the absence of USP9Y expression in females is not
compensated by higher USP9X expression in females as compared to
males (shown are only the significant p values relative to the 12–
20 years age group in the same gender: *p < 0.05, **p < 0.01,
***p < 0.001)
Fig. 3 Representative pictures of usp9 morphants and controls. Two-day-old usp9 e2i2 morpholino injected larvae (c and d) displayed no phenotypic
differences when compared to their corresponding controls (a and b; scale bar = 100 um)
Mol Neurobiol
http://www.ariadnegenomics.com), and GeneCards [18].
MAPT transcriptional regulators were filtered according to
the consistency of their expression alterations and the
decrease of MAPT levels observed in the DU145 USP9X/Y
knockdown gene expression data with their reported
regulatory effect on MAPT. One known MAPT transcription
repressor, BACH1 [39], was found to have increased
expression levels in the USP9X/Y knockdown for five out of
seven filtered genetic probes and for seven out of eight filtered
probes for the USP9X knockdown (see Suppl. Table S1). By
investigating BACH1 upstream regulators using regulatory
interactions from the ResNet Mammalian database, a mech-
anistic link between BACH1 and USP9 was found. Since
USP9 is known to deubiquitinate SMAD4 [16], loss of
USP9 orthologs disables SMAD4-dependent responses in
several model systems [16], and SMAD4 knockdown has
been shown to constitutively activate BACH1 expression
[40], and theUSP9X/Y knockdown effect onBACH1 expres-
sion and its downstream targetMAPTcan be explained by an
inhibition of the common monoubiquitinated SMAD4 (see
also our proposed mechanistic model for the involvement of
USP9 in MAPT expression regulation in Fig. 6b).
Specifically, SMAD4 is monoubiquitinated by the E3
Monoubiquitin Ligase TRIM33 (Ectodermin/Tif1γ),
inhibiting SMAD4 responses, an action which is opposed
by the deubiquitinase USP9 [16].
Overall, in spite of a higher variance across replicate sam-
ples in the USP9X knockdown, a highly significant Pearson
correlation between the log-fold expression changes for the
USP9X/Y and the USP9X knockdown was observed both
across the entire DU145 transcriptomics dataset (r = 0.56,
p < 2.2E−16) and in particular when considering only the top
1000 most significant shared genetic probes (r = 0.965,
p < 2.2E−16), which are expected to be less strongly affected
by random variation than the entire set of transcripts.
Furthermore, no significant difference in the alterations be-
tween the significantly differentially expressed genes in the
USP9X/Y knockdown and the USP9X knockdown could be
detected. This observation may result from a shared functional
profile of USP9X and USP9Y, or alternatively, from a lack of
statistical power to detect smaller differences in downstream
gene expression changes or an insufficient specificity of the
knockdowns. In the USP9X knockdown, a small but not statis-
tically significant decrease in USP9Y expression was observed
in the qRT-PCRmeasurements (p = 0.759), whichmay indicate
a weak off-target effect of this knockdown on USP9Y.
Regarding the possibility of a lack of statistical power to
Fig. 4 Boxplots for the normalized expression of the target genes usp9 and mapta and maptb, assessed after usp9 (e2i2) morpholino knockdown in
2 days postfertilization zebrafish embryos (*p < 0.05, **p < 0.01, ***p < 0.001)
Fig. 5 NormalizedMAPT expression levels on log-scale in the USP9XY
andUSP9X knockdowns (KD) and the scrambled control (scrambled) for
the MAPT genetic probe with the highest average expression in the
DU145 microarray dataset. Decreased median MAPT expression levels
are observed for both knockdowns (p = 0.017 for the USP9XY
knockdown and p = 0.44 for the USP9X knockdown)
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reliably detect small gene expression differences between the
knockdowns, this cannot be excluded, but the high correlation
of fold changes observed across the top 1000 shared genetic
probes, which include a majority of probes with small effect
sizes in their alterations in the individual differential expression
analyses, does not point to any significant shifts in expression
pattern, and no clear outliers were observed that would indicate
a biologically meaningful difference for specific genes between
the knockdowns. Alterations for genetic probes ranked lower
than the top 1000 have too small effect sizes or too high vari-
ation to be distinguished from random variation (these probes
all have adjusted p values for differential expression of at least
0.45). In summary, we could not detect robust gene expression
differences between the knockdowns or indications of such
differences that would warrant a qPCR validation and could
be used for biological data interpretation. Although we cannot
exclude the existence of functional differences between the X-
and Y-forms of USP9 due to the limitations of the omics pro-
filing and knockdown approach, our results rather support the
hypothesis that USP9-related gender differences result solely
from differences in total USP9 expression levels (i.e., the sum
of USP9X and USP9Y expression levels). Given the highly
correlated alteration patterns at the level of single genes in the
two knockdowns, the lack of detectable statistically significant
differences between the knockdowns, and the high protein se-
quence similarity between USP9X and USP9Yof 93%, which
also suggests a high structural and functional similarity, we
have therefore decided to combine the USP9X/Y and USP9Y
knockdown groups for the subsequent analyses to increase the
statistical power for the investigation of pathway and network
alterations.
Pathway and Network Analysis of USP9 Knockdown Effects
on Gene Expression in DU145 Cells
To identify cellular pathways with jointly altered activity in
the USP9XY and USP9X knockdowns, a pathway enrichment
analysis was performed using the GeneGO software (see
Methods). Table 2 reports the top ten cellular pathways with
an overrepresentation of differentially expressed genes in the
knockdowns. These altered pathways mainly include process-
es related to cytoskeleton remodeling, cell adhesion, and stress
signaling (ordered by significance).
Studying the molecular network regions associated with
cytoskeleton remodeling in more detail revealed pronounced
expression changes in several tubulins and microtubule-
associated genes (e.g., TUBA1B, TUBA3C, TUBA3E,
TUBA4B, TUBB2A, TUBB4A, TUBB8, MAP2, and MAP4).
Overall, tubulins tend to have reduced expression in the
knockdowns with few exceptions (e.g., TUBA8 and
TUBG2). Supplementary Fig. S1 shows a corresponding sub-
network from the pathway BRegulation of cytoskeleton pro-
teins in oligodendrocyte differentiation and myelination^ (ad-
justed p value: 2.28E−05). More specifically, the figure high-
lights that tubulins involved in binding interactions with
microtubule-associa ted pro te in tau (MAPT) are
underexpressed, matching with the decreased expression ob-
served forMAPT itself (see above). These results suggest that
the underexpression ofMAPT in the USP9XY/USP9X knock-
downs is part of a broader response affecting a subnetwork
involvingMAPT and tubulins within cytoskeleton regulation-
associated processes. The increased expression of the tran-
scription factor BACH1, which represses MAPT expression,
Fig. 6 aRole of USP9 in the regulation ofMAPT phosphorylation using
relations derived from the literature (see labels of the directed edges). b
Proposed model for the role of USP9 in the regulation of MAPT gene
expression, derived from the upstream analysis of the DU145
transcriptomics data. In both a and b, genes/proteins are represented by
ellipses and colored blue for transcription factors, beige for kinases, and
green for all other proteins. Small blue arrows pointing downward
represent genes with decreased mRNA levels after USP9X/Y
knockdowns in DU145 cells, and red arrows pointing upward highlight
increased mRNA levels observed after the knockdowns
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may partly explain these changes, since multiple tubulins are
predicted as further target genes repressed or activated by
BACH1 according to the SABioscience DECODE database
(www.sabiosciences.com), including TUBA1A, TUBA1C,
TUBA4A, TUBA4B, TUBA8, TUBB, TUBB2A, TUBB2C,
TUBB3, TUBB6, TUBD1, TUBG2, and TUBGCP2. The
DECODE database contains binding site predictions derived
from SABioscience’s proprietary Text Mining Application
and manual genome annotations from the UCSC Genome
Browser [41] ( the database was queried via the
SABioscience BChampion ChiP Transcription Factor Search
Portal^ at www.sabiosciences.com, searching for the
transcription factor BACH1 and setting the species to
BHuman^). Interestingly, USP9X has previously also been
found to associate with microtubules in neuronal processes
and to interact in vivo with doublecortin (DCX), a
microtubule-associated protein involved in neuronal migra-
tion [42].
Network Model of USP9 Knockdown Effects on MAPT
Phosphorylation and Expression
In Fig. 6, we combine information from the literature on the
involvement of USP9 in MAPT phosphorylation regulation
(Fig. 6a) and our findings from the upstream network analysis
in a mechanistic model for USP9-mediated regulation of
MAPT gene expression (Fig. 6b). As outlined in Fig. 6a, pre-
vious evidence from the literature shows that USP9 can influ-
ence the phosphorylation of MAPT both by deubiquitinating
the kinase MARK4 [26], which directly phosphorylates
MAPT, and by deubiquitinating SNCA [30], which mediates
the connection between glycogen synthase kinase 3β
(GSK3B) and its phosphorylation target MAPT [31]. MAPT
expression can be altered by USP9-mediated deubiquitination
of the transcription factor SMAD4 [16], which represses
BACH1 transcription. BACH1, in turn, encodes a transcrip-
tional repressor for MAPT [39] (see Fig. 6b).
Additional functional relationships between USP9 and the
cytoskeleton are suggested by the interactomes of MARK4
and BACH1. Apart from MAPT, MARK4 also phosphory-
lates further tau family microtubule-associated proteins
(MAPs) [27]. The transcriptional MAPT repressor BACH1
has several additional tubulin targets, explaining why tubulins
are underexpressed in the USP9X/Y knockdown (see Suppl.
Fig. S1).
Interestingly, MARK phosphorylation of tau family MAPs
has been shown to trigger microtubule disruption [43], and
inhibitors of tau and MAP phosphorylation have previously
been proposed as drug targets for Alzheimer’s disease (AD).
For example, GSK3B inhibition via small molecule ligands
has been suggested as a possible therapeutic intervention strat-
egy to counteract MAPT hyperphosphorylation in AD [44],
and heat shock protein 70 (HSP70), which suppresses alpha-
synuclein (SNCA)-induced MAPT phosphorylation via
GSK3B through direct binding to SNCA, has also been pro-
posed as a therapeutic target [31]. In a similar fashion, modu-
lation of USP9X/Y activity could be of interest as a new inter-
vention strategy to alter both the phosphorylation of MAPT
(via MARK4 or SNCA/GSK3B, as outlined in Fig. 6a) and
MAPT expression levels (via SMAD4 and BACH1, see
Fig. 6b).
Conclusions
The human brain transcriptome displays several significant
gender differences with large effect size, which may influence
the risk for brain disorders and the severity of their phenotypic
Table 2 Top ten cellular pathways enriched in differentially expressed
genes in theUSP9XYandUSP9X knockdown samples as compared to the
controls, sorted by p value significance (column headers are defined as
follows: Total = total number of biomolecules in the pathway;
FDR = false-discovery rate; In Data = total number of pathway
members among the differentially expressed genes in the USP9XY
knockdown samples)
No. GeneGO top-ranked pathways Total p value FDR In Data
1 Cytoskeleton remodeling 102 3.49E−16 3.09E−13 84
2 TGF, WNT and cytoskeletal remodeling 111 9.24E−16 4.10E−13 89
3 Role of PKR in stress-induced antiviral cell response 57 3.81E−11 1.13E−08 50
4 Positive regulation of STK3/4 (Hippo) pathway and negative regulation of YAP/TAZ function 70 7.25E−11 1.61E−08 58
5 Chemokines and adhesion 100 3.23E−10 5.74E−08 75
6 EGFR signaling pathway 71 9.75E−09 1.44E−06 56
7 Epigenetic regulation of gene expression 57 2.51E−08 2.87E−06 47
8 SLE genetic marker-specific pathways in antigen-presenting cells (APC) 84 2.59E−08 2.87E−06 63
9 TNFR1 signaling pathway 43 2.98E−08 2.93E−06 38
10 Regulation of epithelial-to-mesenchymal transition (EMT) 64 4.13E−08 3.66E−06 51
A significance threshold for individual genes of p < 0.05 was used, and only pathways with a minimum of ten mappable genes were considered
Mol Neurobiol
manifestations. In particular, in this study, we observe gender-
specific differences in the age-dependent decrease of brain
gene expression levels for the microtubule-associated protein
tau (MAPT), a protein playing a central role in neurodegener-
ative diseases referred to as tauopathies. In a joint analysis of
multiple transcriptomics datasets from independent studies,
we identifyUSP9 as a candidateMAPT regulator behind these
gender differences. Previous studies have shown that USP9
can influence the phosphorylat ion of MAPT via
deubiquitination of the MAPT-phosphorylating kinase
MARK4 and indirectly via deubiquitination of SNCA, which
stimulates MAPT phosphorylation by mediating its connec-
tion with the kinase GSK3B. At the gene transcription level,
USP9 knockdown experiments in zebrafish and the DU145
human cell culture result in reducedMAPT levels, confirming
the positive correlation between USP9 andMAPTobserved in
human brain transcriptomics datasets.
A mechanistic explanation for this correlation is provided
by the upstream network analysis of the USP9 knockdown
transcriptome, exploiting existing molecular interaction data
and identifying a regulatory relation between USP9 and
MAPT via the USP9 deubiquitination target SMAD4 and the
MAPT transcription repressor BACH1, whose transcription is
in turn repressed by SMAD4. This potential pathway merits
further validation and investigation with regard to a putative
relevance for AD molecular pathology and intervention strat-
egies. Since the transcription factor BACH1 is predicted to
target multiple tubulins and the kinase MARK4 is involved
in the phosphorylation of multiple microtubule-associated
proteins (MAPs), the alterations in these regulators also pro-
vide a parsimonious explanation for the main changes ob-
served in the pathway and network analysis of the USP9
knockdown effects. Overall, the pathway/network analysis
shows that cellular processes related to cytoskeleton remodel-
ing, as well as tubulins and MAPs in the interaction network
around MAPT, are most significantly affected.
In summary, in the context of prior knowledge from the
literature, the presented transcriptomics data supports the ex-
istence of mechanistic links between USP9 and MAPT and
suggests that USP9 could be of biomedical interest as a regu-
lator modulating both the expression and phosphorylation of
MAPT. For tauopathies like Alzheimer’s disease, involving
aggregations of paired helical filaments of MAPT into neuro-
fibrillary tangles, USP9 may therefore warrant further study as
a target for the development of new intervention strategies.
Materials and Methods
Gene Expression Data Processing and Analyses
All raw microarray datasets from Affymetrix platforms were
preprocessed and normalized using the GC-RMA approach
[45]. For the dataset from the study by Zhang et al., derived
fromRosetta/Merck Human 44 k 1.1 chips and not suitable for
the GC-RMA procedure, the preprocessed data according to
the procedures in the original publication was used [19].
Differential gene expression was scored and analyzed using
the empirical Bayes moderated t-statistic [46], and the
resulting p value significance scores were adjusted for multi-
ple hypothesis testing following the approach by Benjamini
and Hochberg [47].
To account for differences in brain regions covered across
the microarray datasets used, we focused on genes that
displayed consistent, multiregional expression changes in the
HBT dataset [14] (NCBI GEO dataset series GSE25219) and
the late-onset AD case/control dataset [19] (NCBI GEO
dataset series GSE44772), i.e., genes with consistent signs
for the logarithmic fold changes and with overall significant
p values after adjustment for multiple hypothesis testing (ad-
justed p value <0.05). While the GSE25219 dataset covers 16
brain regions (see the section BUSP9Y displays significant
gender-linked expression in the adult brain and diminished
expression in Alzheimer’s disease^), the GSE44772 dataset
covers three regions (the prefrontal cortex, visual cortex, and
cerebellum, which represent higher-level groupings of brain
regions that overlap with the 16 brain regions for the
GSE25219 dataset). The reason for focusing on genes with
consistent expression alterations across multiple brain regions
is that additional evidence for corresponding multiregional
alteration patterns can be collected across datasets from other
studies, which cover the same or further brain regions. For the
gene of interest derived from the analyses on the GSE25219
and GSE44772 dataset,USP9Y, which showed both consistent
multiregional gender-linked expression (GSE25219 dataset)
and multiregional gender-specific expression alterations in
AD (GSE44772 dataset), two further microarray datasets were
studied to investigate whether the significantly reduced ex-
pression in male AD patients as compared to unaffected male
subjects observed on the GSE44772 dataset across the pre-
frontal cortex, visual cortex, and cerebellum, could also be
found in the brain regions covered by other AD case/control
datasets. Specifically, significant multiregional expression
changes forUSP9Ywere confirmed in the NCBI GEO dataset
GSE5281 [20] (covering the brain regions primary visual cor-
tex, entorhinal cortex, hippocampus, medial temporal gyrus,
posterior cingulated, and superior frontal gyrus), and a
matching qualitative change was observed in hippocampal
samples of the NCBI GEO dataset GSE28146 [21] (see the
section BUSP9Y displays significant gender-linked expression
in the adult brain and diminished expression in Alzheimer’s
disease^).
A limitation of these investigations of consistent gene ex-
pression alterations across multiple brain regions is that the
quantitative statistical results for specific brain regions on a
single dataset cannot be directly integrated with the statistics
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obtained from independent datasets covering distinct brain
regions to increase the statistical power. However, by using
datasets with large sample sizes and coverage of multiple
brain regions to identify genes with multiregional consistent
expression changes, a qualitative confirmation of multiregion-
al expression alterations is possible on independent datasets,
which may partly cover distinct brain regions (comparing the
statistics on the separate datasets, instead of integrating them
into a single statistic).
To exclude age-related biases in the significant findings for
the analyses of microarray datasets from the AD case/control
studies, the significance of gene expression alterations be-
tween patients and controls was confirmed after adjustment
for age using a surrogate variable analysis (R software pack-
age SVA [48]). As a separate investigation related to aging-
associated changes, a transcriptome-wide analysis and com-
parison of brain gene expression alterations during adult aging
and in the neurodegenerative disorders Alzheimer’s and
Parkinson’s disease has been presented previously [49].
To conduct cellular pathway analyses, the differential ex-
pression analysis results for the combined knockdown sam-
ples as compared to the control samples were used as input for
the GeneGO pathway analysis software [50], filtering out ge-
netic probes with a p value above 0.05. Pathways with an
overrepresentation of differentially expressed genes were
ranked by increasing p value. For the upstream network anal-
ysis, literature-curated TF-target relationships from the
Biobase Proteome™ database (see http://www.biobase-
international.com/proteome-2) and GeneCards [18] were
used, and the consistency of potentially relevant TF-target
pairs with the alteration patterns observed in the transcripto-
mics data was checked.
For qRT-PCR measurement analyses, the data was normal-
ized against the mean of multiple reference genes according to
the method byHellemans et al. [51] (see details on the selected
reference genes and the experimental design in the BMethod^
sections on the zebrafish and cell culture experiments). The
Welch’s t test was then applied to assess the significance of
differential expression (changes with a significance of
p < 0.05 are highlighted by star symbols in the corresponding
boxplots, see Fig. 4).
Zebrafish Experiments
Knockdown Experiments The usp9 antisense morpholino
(MO) was designed and synthesized to target the splice donor
site of exon 2 (5′-TGAAAATGGTGCTCTGACCTGGTTC-
3′) and to interfere with normal pre-mRNA splicing of the
zebrafish usp9 gene (ENSDART00000135384). To analyze
gene expression changes after usp9 antisense morpholino
MO knockdown in zebrafish for the target genes usp9, and
the zebrafish MAPT paralogs mapta and maptb, titrated mi-
croinjections were performed with 4.8 and 8 ng/injection of an
e2i2 splice blocking usp9 MO in one to two cell-stage
zebrafish embryos. Control MO (randomized 25 N oligomer,
8 ng/injection) and wild-type embryos (non-injected controls)
were processed in parallel. All MOs were designed and syn-
thesized byGene Tools. Embryos were maintained in standard
conditions (28 °C) in embryo medium (0.3× Danieau’s). Two
days after microinjection, 20 dechorionated embryos per con-
dition were processed for RNA extraction and reverse tran-
scription. For each target gene to be assessed via qRT-PCR
gene expression measurements (LightCycler®480, Roche),
three different pairs of primers were initially tested for speci-
ficity, and then the most specific pair was selected for further
experiments (see Suppl. Table S2). Three zebrafish house-
keeping (HK) genes were processed in parallel (β-actin1,
elongation factor 1, and 60S ribosomal protein L13). The
qRT-PCR was performed with five biological replicates per
condition, and each biological replicate was covered by four
technical replicates.
Cell Culture Experiments
In order to studyUSP9X/Yand its gene regulatory network in a
cell culture model, relevant human cell lines were first com-
pared in terms of the stability of USP9X, USP9Y, and MAPT
and expression using information from the literature and pub-
lic gene expression data. The prostate carcinoma cell line
DU145 was chosen, since the public transcriptomics data
showed stable expression for the genes of interest (USP9Y,
USP9X, MAPT), as opposed to the alternative neuroblastoma
cell line from female origin SH-SY5Y (ATCC no. CRL-2266,
undifferentiated) and the human embryonic kidney cell line
HEK293 (ATCC no. CRL-1573, see Suppl. Fig. S2 and S3
and Suppl. Tables S3 and S4). Since DU145 cells are derived
from a non-neuronal tumor tissue, the molecular regulatory
network aroundUSP9 present in this cell line can only provide
an approximation to a corresponding network in a genetically
stable, neuronal cell population. Possible limitations include
that yet unknown regulatory genes in this network and down-
stream effectors of USP9 with tissue-specific expression in
primary neuronal cells may not be expressed in DU145 cells,
and that like in other tumor cell lines, the metabolism may be
shifted toward proliferation and growth.We therefore consider
the analysis of USP9 in DU145 cells in combination with our
findings in the zebrafish model, the analyses of human brain
microarray data, and information from the published litera-
ture, to avoid over-reliance on a single model and information
source.
DU145 cells were obtained from the American tissue cul-
ture collection (ATCC no. HTB-81). Cells were cultured in
Dulbecco’s modified eagle medium (Invitrogen no. 41966-
029) containing high glucose (25 mM), L-glutamine (4 mM),
and sodium pyruvate (1 mM). This medium was supplement-
ed with 10% v/v heat-inactivated fetal bovine serum
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(Invitrogen no. 10500-064). Cells were grown at 37 °C at 5%
CO2 and saturated humidity.
Knockdown plasmids were designed to either targetUSP9X
and USP9Y jointly or USP9X specifically. Due to the high
sequence homology between USP9X and USP9Y, the produc-
tion of potentially unspecific USP9Y shRNA plasmids was
omitted. Hairpin sequences (Suppl. Tab. S5) and U6 promoters
were subcloned into FastBac plasmids (PMID 15771966). The
list of all primers tested for the knockdown experiments is
provided in Suppl. Tab. S3, and the agarose gel electrophoresis
results are shown in Fig. S3. While multiple shRNA constructs
per target gene were designed and tested for knockdown effi-
ciency via gene expression analysis in whole-cell populations,
for each target only, the construct with the best knockdown
efficiency was used for subsequent profiling. As the efficiency
of gene silencing may vary for different shRNA constructs and
off-target effects can occur in some cases, limitations may arise
in the interpretation of data derived from the use of a single
construct. However, since the highly significant inhibition of
the target genes observed in both microarray and qRT-PCR
expression measurements (see the section BGene-level expres-
sion analysis of USP9 knockdown effects in DU145 cells^)
was not matched or approximated by expression changes ob-
served in any other gene in the differential expression ranking
derived from the microarray data, at least a strong off-target
alteration can be excluded, as well as a scenario in which a
larger amount of the target transcripts escapes the inhibition
to recover the normal function. Transfection into DU145 was
done via Lipofectamine 2000 (Invitrogen no. 11668019) and
transfected cells were incubated for 48 h. Prior to RNA extrac-
tion, the perturbed cells were enriched via fluorescence-
activated cell sorting. RNA was extracted using the Qiagen
RNeasy Mini Kit (Qiagen no. 74106) and treated with
DNaseI (Qiagen no. 79254). Reverse transcription was done
as described previously (PMID 26738520). For microarray ex-
pression profiling, RNA extracts were prepared using the
GeneChip WT PLUS Reagent Kit (Affymetrix, Manual P/N
703174 Rev. 2 and UserGuide GeneChip Expression Wash,
Stain and Scan for Cartridge Arrays P/N 702731 Rev. 4).
RNA quality and integrity was checked using a NanoDrop
ND-100 spectrophotometer (Thermo Scientific) and the 2100
Agilent Bioanalyzer (Agilent), respectively. The purified,
sense-strand cDNA was fragmented by uracil-DNA
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1
(APE 1) at the unnatural dUTP residues. The fragmented
cDNA was labeled by terminal deoxynucleotidyl transferase
(TdT) using the Affymetrix proprietary DNA Labeling
Reagent that is covalently linked to biotin. Single-stranded
cDNA (5.5 μg) was used for fragmentation and labeling, and
the GeneChip Hybridization, Wash and Stain Kit was used to
hybridize and wash the cartridges. Control Oligonucleotide B2
and 20X Eukaryotic Hybridization Controls were added to the
hybridization cocktail containing the labeled sample and
injected into the cartridge. The incubation lasted 16 h at
45 °C with a rotation at 60 rpm. Then, the Fluidics Station
450/250 was used to wash and stain the Affymetrix
GeneChip Human Gene 2.0 ST probe arrays. The probe arrays
were scanned after completion of the wash protocols using the
Affymetrix GeneChip Scanner 3000.
Data was processed as described in the BMethods^ section
on gene expression data processing and analysis. Both the raw
and processed data have been deposited in the Gene
Expression Omnibus (GEO) database under the series acces-
sion number GSE79376.
For validation of microarray-derived gene expression data
in USP9 knockdown conditions, shRNA perturbations in
DU145, cell sorting, RNA extraction, and reverse transcrip-
tion were redone as described above. Real-Time PCR expres-
sion measurements for the target genes of interest and six
reference genes were performed using a Fluidigm 48.48 inte-
grated fluidic circuit array. The six reference genes consisted
of three genes commonly used as reference for human cell
culture RNA expression measurements (PPIA, GAPDH, and
PDHB) and three genes displaying the lowest variation in the
processed Affymetrix GeneChip microarray data for the
DU145 cells (EIF4G2M, HSPA8, and UBAP2L). The assay
IDs and catalog numbers for the TaqMan® gene expression
assays used for the target and reference genes are provided in
Suppl. Table S6. For each condition (USP9X/Y knockdown,
USP9X knockdown, and three scrambled RNA control sam-
ples) measurements were obtained for five biological
replicates.
To preprocess and analyze the raw data from the Fluidigm
platform, an optimal subset of two reference genes (PPIA and
HSPA8) was determined using the method by Vandesompele
et al. [52] as implemented in the R software package SLqPCR
(http://www.bioconductor.org). After determining the median
across the measurements for the selected reference genes, a
ΔCt calculation was performed as described in Yuan et al.
[53] and the empirical Bayes moderated t-statistic [46] was
applied to compare USP9X/Y knockdown samples against
controls.
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